Aims IA-2 is a transmembrane protein found in the densecore vesicles (DCV) of neuroendocrine cells and one of the major autoantigens in type 1 diabetes. DCV are involved in the secretion of hormones (e.g., insulin) and neurotransmitters. Stimulation of pancreatic b cells with glucose upregulates the expression of IA-2 and an increase in IA-2 results in an increase in the number of DCV. Little is known, however, about the promoter region of IA-2 or the transcriptional factors that regulate the expression of this gene. Methods In the present study, we constructed eight deletion fragments from the upstream region of the IA-2 transcription start site and linked them to a luciferase reporter.
Introduction
IA-2 and IA-2b (also known, respectively, as ICA512 and Phogrin) are dense-core vesicle (DCV) transmembrane proteins and major autoantigens in type 1 diabetes [1, 2] . Human IA-2 and IA-2b are 979 and 1,015 amino acids, respectively, in length (GenBank Acc. No., NM_002846.3 and NM_002847.3). Both proteins are encoded by 23 exons and consist of an intracellular, transmembrane and luminal domain [3] . The genomic DNA sequence of the human IA-2 gene is 20 kb, whereas that of IA-2b spans approximately 1,000 kb. Both genes are widely distributed in neuroendocrine cells throughout the body and are abundantly expressed in the pancreatic islets, pituitary and hippocampus.
Recently, we showed that deletion of the IA-2 and/or IA-2b genes in mice results in a decrease in the number of DCV, impairs insulin secretion [4] , leads to female infertility, alters behavior and results circadian dysregulation [5] . In contrast to the deletion of these genes, overexpression of IA-2 in insulin-secreting MIN6 cells results in an increase in the number of DCV and the secretion of insulin [6] . These findings show that IA-2 and IA-2b are important molecules involved in the secretion of insulin and other neurohormones and neuropeptides.
Despite the extensive studies on the properties and function of IA-2, little is known about the promoter region or transcriptional factors that regulate the expression of this gene. In the present experiments, using deletion fragments from the 5 0 -upstream region of the IA-2 transcription start site, we identified a short sequence with strong promoter activity and transcriptional factors that bind to this region.
Materials and methods

IA-2 promoter-luciferase assay
Eight consecutive human IA-2 promoter fragments (-1,300 to ?115) were cloned in the pGL3 vector to drive the expression of the firefly luciferase reporter gene (Promega, Madison WI, USA) [3] . All constructs were confirmed by Sanger sequencing. A dual-luciferase reporter system was used for promoter activity measurement according to the manufacturer's instruction (Promega). Renilla luciferase was used as an internal control for transfection efficiency. Normalized luciferase data (firefly/renilla) were compared with the empty pGL3-basic vector. The construct pIA2-8 or pGL3 vector served as a control for basal levels. The cell line HEK293 also was included as a control because endogenous IA-2 expression was not detected. In a separate experiment, inserts of pIA2-1, pIA2-2, pIA2-6, pIA2-7 and pIA2-8 also were inserted into the pGL4 luciferase reporter vector (Promega) for comparison of luciferase activities measured from the corresponding pGL3-based constructs. Unless otherwise indicated the pGL3 vector was used in all experiments.
Cell culture and transfection
Four cell lines (HEK293, U87MG, AtT20 and MIN6) were cultured in RPMI 1640 or Dulbecco's modified Eagle medium supplemented with 5.6 mM glucose and 10 % fetal bovine serum as described previously [6, 7] . AtT20 cells were commercially obtained (ATCC, Manassas, VA, USA). MIN6 cells were obtained from Dr. Jun-ichi Miyazaki [8] and used between passages 37 and 42, which responded to high glucose by a 5-6-fold increase in insulin secretion and also responded to forskolin and IBMX treatment [9] . Cells were transfected with 3 lg of appropriate luciferase reporter plasmid by lipofectamine 2000 (Invitrogen Corp., Carlsbad, CA, USA), which resulted in approximately 50 % transfection efficiencies at 48 h. Plasmid coding for Renilla luciferase (0.03 lg) was cotransfected with each of the reporter gene constructs. After transfection, cells were cultured for 24-48 h and lysed in passive lysis buffer (Promega) for measurement of luciferase activity using a microplate luminometer (Berthold Technologies, Germany).
Site-directed mutagenesis of the IA-2 promoter
The GeneEditor site-directed mutagenesis system (Promega) was used to generate mutations in the sequence of CRE-L and CRE.2-binding sites. RNAi and real-time PCR MIN6 cells were cultured in 12-well plates and transfected with final concentration 50 nM of CREB RNAi (Mm_Creb1_1, SI00959035, Qiagen, Valencia, CA, USA) or with an unrelated RNAi (Gapdh, Mm_Gapd_3, SI01009393, Qiagen) using HiPerfect transfection reagent (Qiagen). Incubation time (for 1, 12, 24, or 48 h) of the RNAi reagents in MIN6 cell was compared and optimized for the best inhibitory effect on CREB expression. No cell toxicity was observed for CREB RNAi. Total RNA was extracted using Trizol (Invitrogen), and CREB and IA-2 mRNA expressions were quantified using RT-PCR Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was conducted as previously described [7] . Primers and probes of mouse IA-2 (Assay ID Details, Mm01258989_m1), CREB (Assay ID, Mm00501607_m1), and Gapdh (Assay ID, Mm99999915_g1) were purchased from Applied Biosystems. Real-time amplification of cDNAs was performed using the TaqMan Universal Master Mix and the primers in 9700HT real-time PCR Cycler (Applied Biosystems).
Statistical analysis
All experiments were performed independently at least three times, and each experiment consisted of triplicate samples. The significance of differences between groups was analyzed by either Student's t tests or one-way ANOVA and Bonferroni test.
Results
Minimal IA-2 promoter sequence
We previously isolated and sequenced a 3.9-kb 5 0 -upstream region of the human IA-2 gene and found that the 1.3-kb proximal region possessed promoter activity in U87MG cells [3] . In the present study, we attempted to determine the minimal promoter region responding to high glucose or forskolin (a direct cAMP activator for increasing PKA and in turn CREB) stimulation. To do this, we constructed eight different lengths of IA-2-luciferase reporters ranging from -1,300 to ?115 bp (Fig. 1) . Each of the plasmid DNAs was used to transiently transfect HEK293, U87MG, AtT20 and MIN6 cells. After 48 h in culture, the cells were stimulated with either 16.7 mM of glucose or 10 lM of forskolin (Fig. 1) , and IA-2 promoter-luciferase activity was determined using the microplate luminometer. With high glucose, the activity of pIA2-2 (-826 to ?115) reporter was increased[eightfold in MIN6 and AtT20 cells and about fivefold in U87MG cells as compared to the basal reporter pIA2-8 (?1 to ?115) or the embryonic kidney HEK293 cells. The activity of pIA2-1 (-1,300 to ?115) was substantially less than that of pIA2-2, suggesting the existence of potential transcriptional repressor(s) in the region of -1,300 to -826. All the constructs from pIA2-2 to pIA2-7 showed some degree of responsiveness to glucose. In contrast, pIA2-8 did not respond to to ?115 bp) were constructed and cloned into the luciferase reporter pGL3 vector, and transfected into HEK293, U87MG, AtT20, and MIN6 cells. The pRL-TK vector, coding for Renilla luciferase, was cotransfected as an internal reference, and luciferase values were normalized to Rluc activity. Transfection was carried out in triplicate, and each experiment was repeated three times. Cells were treated with either (upper panel) high glucose (16.7 mM) or (lower panel) forskolin (10 lM). Data (mean ± SE) are presented as luciferase activity relative to that of the promoter-less pGL3 basic vector (i.e., pIA2-8) in each cell line. Three independent experiments were performed. The X axis of the graph indicates fold-activation over normalized luciferase activities Acta Diabetol (2015) 52:573-580 575 glucose indicating that there were no glucose-associated regulatory elements in that region of the promoter. Forskolin produced even greater changes in luciferase activity than glucose. As seen in Fig. 1 (lower panel) , forskolin significantly increased luciferase activity (10-16 folds) in MIN6 and AtT20 cells that had been transfected with the reporter plasmids from pIA2-1 to pIA2-6. No luciferase activity was observed in the cells that had been transfected with the reporter plasmids pIA2-7 or pIA2-8 ( Fig. 1) , indicating that the region from -94 to ?115 bp did not contain regulatory elements for forskolin stimulation.
Because of lower background activity in the pGL4 vector as compared to the pGL3 vector, in a separate experiment the pGL4 vector was used with inserts from pIA2-1, pIA2-2, pIA2-6, pIA2-7 and pIA2-8. The pGL4 constructs yielded results similar to what we obtained with the pGL3 construct although the fold changes were slightly lower ( Supplementary Fig. 1 ).
To see, if forskolin, which our experiments showed activated the IA-2 promoter constructs, would actually increase endogenous IA-2 levels, MIN-6 cells were treated with forskolin and at different times thereafter IA-2 mRNA was measured by real-time PCR (Fig. 2) . By 1 h, IA-2 mRNA levels were increased 1.5-to 2-fold, and by 24-48 h, they were increased sixfold. Since forskolin is a known activator of cAMP, we tested the ability of IBMX (3-isobutyl-1-methylxanthine), another known activator of cAMP, to increase IA-2 mRNA. By 1 h, IA-2 mRNA levels were increased about twofold, and by 24-48 h they increased 3.0-to 3.5-fold, consistent with previous studies [6, [10] [11] [12] . Glucose served as a positive control and PMA (Phorbol 12-myristate 13-acetate), which does not activate cAMP, served as a negative control.
CRE transcription-binding sites and mutagenesis of these sites
Using the comparative promoter sequence analysis program (TRES) [13] , we analyzed the IA-2 promoter sequences in several mammalian species to look for evolutionary conserved transcription-binding sites. Multiple sequence alignment identified two potential CRE-binding sites (e.g., CRE-L and CRE.2) in the -216 to -128 region of human (h), rat (r), and mouse (m) IA-2 (Fig. 3) . In addition, two conserved SP1-binding sites were found in the -128 to -40 region of these three species.
To determine whether the two CRE-binding sites were functional, we mutated CRE-L or CRE.2 or both, and transfected each of the plasmids into MIN6 cells. After 48 h treatment with or without forskolin and/or IBMX, IA-2 promoter-luciferase activity was measured. The activity of IA-2 luciferase in wildtype promoter was increased about 16-fold by forskolin and about eightfold by IBMX over basal activity (Fig. 4 upper panel) . The IA-2 luciferase activity, however, was significantly decreased when the CRE-L or the CRE.2-binding sites were mutated. When MIN6 cells were transfected with both mutated CRE-L and mutated CRE.2, IA-2 luciferase activity was reduced to a level near Basal  1h  12h  24h  48h  1h  12h  24h  48h  1h  12h  24h  48h  1h  12h  24h  48h IA-2 mRNA levels in MIN6 cells (% of basal) that of the basal control, pIA2-7. These observations indicate that the CRE-L and CRE.2-binding sites are required for forskolin-or IBMX-induced promoter activity.
Endogenous CREB protein binds to CRE-binding sties
To see whether CREB protein actually binds to the CREbinding sites of the IA-2 promoter in MIN6 cells, we used ChIP assay. After immunoprecipitation with CREB antibody, precipitated DNAs were PCR amplified by specific primers for the CRE-L-or CRE.2-containing regions of the IA-2 promoter. As seen in Fig. 4 (lower panel) , both CREcontaining fragments, but not the flanking regions that do not contain the CRE-binding site, were efficiently precipitated and amplified. These findings show that the CREbinding sties and the transcriptional factor CREB play an important role in regulating the expression of IA-2.
Knockdown of CREB affects IA-2 promoter activity
To confirm the effect of CREB on IA-2 promoter activity, we knocked down CREB expression in MIN6 cells by RNAi. After 48 h treatment with CREB-specific RNAi, endogenous CREB and IA-2 levels were evaluated by realtime PCR. Figure 5 (upper-left and lower-left panels) shows that both CREB mRNA and IA-2 mRNA were significantly reduced in MIN6 cells, thereby supporting the argument that the expression of CREB affects endogenous IA-2 expression at the level of transcription. Western blotting with anti-CREB antibody also showed that the CREB protein level was significantly decreased in MIN6 cells by CREB RNAi treatment, but not by Gapdh RNAi (Fig. 5 upper-right panel) . Western blotting with anti-IA-2 antibody also showed reduced IA-2 protein level (Fig. 5  upper-right panel) . As expected, the IA-2 luciferase 
Discussion
As a unique transmembrane protein of DCV, IA-2 has been implicated in insulin secretion and DCV stability [4] . Overexpression of IA-2 increases DCV number and insulin secretion [6] , whereas deletion of IA-2 decreases DCV number and insulin secretion [4] . In the present study, using deletion fragments of IA-2 from the upstream region of the IA-2 transcription start site, we identified a short fragment (-216 to ?115) that has strong promoter activity when stimulated, in particular, with forskolin. The importance of CREB as a critical transcription factor [14] in the -216 to ?115 fragment is strongly supported by the evolutionary conservation in humans, rats and mice of two CREB-binding sites in this region (Fig. 3 ) and by the data described in this paper using site-directed mutagenesis, ChIP and RNAi inhibition. During the course of this work, however, we observed that the knockdown of CREB by RNAi did not completely abolish endogenous IA-2 mRNA expression (Fig. 5 middle  panel) or IA-2-promoter-luciferase activity (Fig. 5 lower   panel) . This suggested that additional transcriptional factor(s) might be involved. One such transcriptional factor could be ATF (Fig. 3) , which is known to bind to the CRE-L-binding site, at least, in the insulin promoter [15, 16] . Whether ATF actually is induced by forskolin and binds to the CRE-binding site of the IA-2 promoter, however, requires further investigation.
Of particular interest, an even shorter upstream region (-94 to ?115), which does not have CREB-binding sites and does not respond to forskolin, still responds to glucose (Fig. 1) . This -94 to ?115 region, however, has one or more glucose-sensitive sites. For example, an SP1-binding site is located in pIA2-7 (-84 to -40 region), and the binding of the SP1 transcription factor is known to make it sensitive to high glucose particularly in TATA-less genes such as IA-2 [3, 17] . Other SP1-binding sites, such as a short fragment containing glucose-elements in the promoter of pyruvate carboxylase (from nt -546 to -399), were recently identified to regulate high glucose-induced gene expression [18] . This argues that glucose and forskolin regulate the transcriptional activity of the IA-2 through different signaling pathways. Alternatively, crosstalk between glucose and cAMP pathway may synergistically regulate the expression of IA-2. For instance, glucose has been found to promote CREB activity by inducing Three independent experiments were performed. The P values (**P \ 0.01; ***P \ 0.001) were calculated by the Student's t test TORC2 nuclear relocalization, which is required for the cAMP-mediated activation of CREB in b cells and islets [19] .
In conclusion, both forskolin and IBMX are known to increase cAMP and that cAMP can stimulate PKA-mediated phosphorylation of the transcription factor CREB [20] . The binding of CREB to the CRE-L and CRE.2-binding sites results in the activation of the IA-2 promoter and an increase in IA-2 mRNA and IA-2 protein. The widespread distribution of CREB and CREB-binding sites throughout the genome [21] may explain the high levels of IA-2 seen in some tissues [22, 23] and tumors [24, 25] , where DCV have not been detected. Viewing the IA-2 promoter region from an even broader perspective, when the 5 0 -upstream region from -1,300 to ?115 was examined by the TRES program, a number of other potential transcription-binding sites and CREB activators were identified [26] [27] [28] [29] [30] . Thus, other transcription factors, depending on their concentration and the tissue type, also may play a role in the regulation and expression of the 5 0 -upstream region (-1,300 to ?115) of the IA-2 gene.
